Ginkgo Bioworks (NYSE:DNA) Issues Quarterly Earnings Results

Ginkgo Bioworks (NYSE:DNA) announced its earnings results on Wednesday. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.15, FiscalAI reports. The business had revenue of $20.16 million during the quarter, compared to analyst estimates of $24.05 million. Ginkgo Bioworks had a negative return on equity of 56.08% and a negative net margin of 215.41%.

Here are the key takeaways from Ginkgo Bioworks’ conference call:

• Revenue fell sharply: Q2 2026 revenue declined 48% year over year to $20 million, while adjusted EBITDA worsened to negative $36 million from negative $25 million.
• Q2 cash burn increased to $45 million from $38 million a year earlier, and excess leased-space costs rose to $14 million; the company nevertheless reaffirmed full-year 2026 cash-burn guidance of $125 million to $150 million.
• Ginkgo reported progress scaling Nebula, its Boston autonomous lab, to 105 racks and said it is operating 24/7 with roughly 30 unique protocols per day, potentially improving service economics and demonstrating the platform to prospective customers.
• The company announced autonomous-lab awards involving MIT, Caltech, the University of Maryland, and Northwestern, expanding its reach into academic research and potentially supporting future lab-equipment, software, and support revenue.
• Ginkgo said its ADME-One service attracted approximately 16 customers in its first six weeks and offers a drug-screening panel for $199, substantially below quoted Western and Chinese CRO pricing, although the company still needs to establish repeat demand and scale.

Ginkgo Bioworks Price Performance

DNA stock traded down $0.73 during mid-day trading on Friday, reaching $7.77. The company had a trading volume of 1,065,197 shares, compared to its average volume of 1,161,208. The company has a market capitalization of $507.73 million, a PE ratio of -1.45 and a beta of 1.78. The firm has a 50 day moving average of $8.80 and a 200 day moving average of $8.33. Ginkgo Bioworks has a 12 month low of $5.37 and a 12 month high of $17.58.

Institutional Trading of Ginkgo Bioworks

Large investors have recently modified their holdings of the company. Invesco Ltd. grew its stake in Ginkgo Bioworks by 23.9% in the fourth quarter. Invesco Ltd. now owns 261,706 shares of the company’s stock worth $2,175,000 after purchasing an additional 50,565 shares in the last quarter. Tudor Investment Corp ET AL bought a new stake in Ginkgo Bioworks during the 4th quarter valued at $1,612,000. Numerai GP LLC raised its position in Ginkgo Bioworks by 94.1% during the 4th quarter. Numerai GP LLC now owns 25,625 shares of the company’s stock valued at $213,000 after purchasing an additional 12,421 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Ginkgo Bioworks by 113.9% in the 4th quarter. Millennium Management LLC now owns 48,901 shares of the company’s stock worth $406,000 after buying an additional 26,037 shares during the period. Finally, Inspire Investing LLC lifted its holdings in shares of Ginkgo Bioworks by 81.4% in the 4th quarter. Inspire Investing LLC now owns 57,293 shares of the company’s stock worth $476,000 after buying an additional 25,716 shares during the period. Hedge funds and other institutional investors own 78.63% of the company’s stock.

Analyst Upgrades and Downgrades

DNA has been the subject of a number of recent analyst reports. Wall Street Zen cut Ginkgo Bioworks from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ginkgo Bioworks in a research note on Friday, July 17th. Finally, TD Cowen downgraded Ginkgo Bioworks from a “buy” rating to a “hold” rating and set a $9.00 target price for the company. in a research report on Friday. One investment analyst has rated the stock with a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Ginkgo Bioworks presently has a consensus rating of “Sell” and an average price target of $7.00.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.

The company’s services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.